文献速递哮喘

2026年GINA哮喘策略报告:执行摘要与关键更新

2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes.
PubMed 文献 · Eur Respir J · 2026-11-05

全球哮喘倡议(GINA)发布2026年策略报告,提供全生命周期哮喘诊疗的循证方法,核心为评估-调整-复查循环的个体化反复照护。强调尽可能客观确认诊断,所有哮喘患者应接受含吸入性糖皮质激素治疗,反对单用短效β2受体激动剂。成人/青少年首选低剂量ICS-福莫特罗作为抗炎缓解剂(AIR)方案。

要点

  • 所有哮喘患者(含多数学龄前儿童)应接受含ICS治疗,反对单用SABA
  • 成人/青少年首选低剂量ICS-福莫特罗AIR方案(按需或维持+缓解)
  • 2026年更新包括扩展AIR选项、严重哮喘生物制剂选择及急性发作管理

核心结论

  • GINA 2026强调基于评估-调整-复查循环的个体化哮喘管理,以控制症状并降低未来风险。

研究设计与样本

  • GINA年度更新的循证策略报告,覆盖全生命周期哮喘诊断、评估、治疗与预防。

主要发现

  • 与基于SABA的方案相比,低剂量ICS-福莫特罗AIR方案大幅减少严重急性发作且使用简便。
  • 2026年关键更新包括扩展成人及儿童AIR选项、修订严重哮喘及生物制剂选择指导、大幅更新急性哮喘管理。

关键数值与推荐

  • GINA强烈推荐所有哮喘患者(成人、青少年、儿童及大多数学龄前儿童)接受含ICS治疗。
  • GINA推荐反对单用SABA治疗。
  • 成人/青少年首选Track 1:低剂量ICS-福莫特罗作为AIR,按需单用或维持加缓解(MART)。

临床怎么用

  • 临床应优先为所有哮喘患者处方含ICS治疗,避免单用SABA。
  • 成人/青少年优先采用低剂量ICS-福莫特罗AIR方案,按需或MART。
  • 严重哮喘需结构化评估:核实诊断、优化可调因素、炎症表型分型、选择生物制剂并管理全身激素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Global Initiative for Asthma (GINA) Strategy Report provides a comprehensive, annually updated evidence-based approach to asthma diagnosis, assessment, treatment, and prevention across the lifespan. Its central approach is personalized, iterative care based on the Assess-Adjust-Review cycle for both symptom control and reduction of future risk (including severe exacerbations, persistent airflow limitation, and treatment-related harm).GINA emphasizes objective confirmation of diagnosis wherever possible, and regular assessment of lung function, inhaler technique, adherence, multimorbidity, risk factors (including Type-2 biomarkers), and patient goals and preferences. GINA strongly recommends that all adults, adolescents, children and most preschoolers with asthma should receive inhaled corticosteroid (ICS)-containing treatment. GINA recommends against short-acting beta2-agonist (SABA)-only treatment. For adults/adolescents, GINA Track 1 using low-dose ICS-formoterol, an anti-inflammatory reliever (AIR), either as-needed-only (AIR-only) or as maintenance-and-reliever therapy (MART), is preferred because of its substantial reduction in severe exacerbations compared with SABA-based regimens, and its simplicity. Age-specific treatment pathways in children also emphasize ICS-containing therapy and exacerbation prevention.For difficult-to-treat and severe asthma, GINA provides structured guidance, emphasizing diagnostic verification, optimization of modifiable factors, inflammatory phenotyping, biologic therapy selection, and (as for all patients) systemic corticosteroid stewardship. Acute exacerbation care incorporates long-term preventive treatment, including post-discharge reassessment of management and action plan.Key 2026 updates include expanded AIR options for adults and children, revised guidance on severe asthma and selection of biologic treatment, and substantial updates to acute asthma management.GINA integrates evidence-based management with shared decision-making, self-management education, implementation, and global advocacy to reduce preventable asthma morbidity and mortality.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Reddel HK, Allan K, Bacharier LB, et al. 2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes. Eur Respir J. 2026. PMID: 42988388. doi:10.1183/13993003.02304-2026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。